Safety and Immunogenicity of a Fully Liquid Vaccine Containing Five‐Component Pertussis‐Diphtheria‐Tetanus‐Inactivated Poliomyelitis‐Haemophilus influenzae Type B Conjugate Vaccines Administered at Two, Four, Six and 18 Months of Age | Zendy

Ronald Gold | Zendy; Luis Barreto | Zendy; Santiago Ferro | Zendy; John Thippawong | Zendy; Roland Guasparini | Zendy; William Meekison | Zendy; Margaret L. Russell | Zendy; Elaine L. Mills | Zendy; Dana Harrison | Zendy; Pierre Lavigne | Zendy

Open Access

Safety and Immunogenicity of a Fully Liquid Vaccine Containing Five‐Component Pertussis‐Diphtheria‐Tetanus‐Inactivated Poliomyelitis‐Haemophilus influenzae Type B Conjugate Vaccines Administered at Two, Four, Six and 18 Months of Age

Author(s) -

Ronald Gold,

Luis Barreto,

Santiago Ferro,

John Thippawong,

Roland Guasparini,

William Meekison,

Margaret L. Russell,

Elaine L. Mills,

Dana Harrison,

Pierre Lavigne

Publication year - 2007

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2007/289842

Subject(s) - medicine , diphtheria , tetanus , vaccination , poliomyelitis , booster dose , immunization , hib vaccine , poliovirus , virology , immunogenicity , inactivated poliovirus vaccine , poliomyelitis vaccine , pediatrics , conjugate vaccine , immunology , antibody , virus

The safety, immunogenicity and lot consistency of a fully liquid, five-component acellular pertussis combination vaccine, comprised of diphteria, tetanus and acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b (DTaP-IPV-Hib [Pediacel, sanofi pasteur, Canada]) were assessed and compared with that of Hib vaccine reconstituted with the five-component acellular pertussis combination vaccine (DTaP-IPV//Hib, Pentacel [sanofi pasteur, Canada]).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research